Corbus Pharmaceuticals Holdings, Inc.: updates and filings

CRBPNASDAQHealthcare · Pharmaceutical Preparations

Price

$2.06

November 20, 2026Market cap $42M

What Ploutos Investor adds for Corbus Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from 2015
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 48% since Nov 10, 2026, when the 10-Q these figures come from was filed ($3.93 then, $2.06 on Nov 20, 2026). The figures date from before that move.10-Q

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 80 daysAround Feb 10, 2027 · for Q4 2026

last Nov 10, 2026next Feb 10, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 9, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 16, 2026Regulation FD disclosure, other material events
    Form8-K
  • Nov 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Nov 2, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 29, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 15, 2026Regulation FD disclosure
    Form8-K
  • Sep 30, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 14, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 6, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 6, 2026Material agreement entered, Regulation FD disclosure
    Form8-K
  • Jun 17, 2026Shares registered for employees
    FormS-8
  • May 29, 2026Shares registered for employees
    FormS-8
  • May 26, 2026Regulation FD disclosure, other material events
    Form8-K
  • May 21, 2026Material agreement entered, officer or director change, Regulation FD disclosure
    Form8-K
  • May 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 14, 2026Officer or director change, shareholder vote, Regulation FD disclosure
    Form8-K
  • May 12, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 12, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Apr 16, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 16, 2026Officer or director change
    Form8-K
  • Apr 14, 2026Regulation FD disclosure, other material events
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 10, 2014.

The full analysis

What do Corbus Pharmaceuticals's filings show?

The filings are where every one of Corbus Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.